Profiles

Bruce Lyons

UTAS Home Dr Bruce Lyons
Bruce Lyons

Bruce Lyons

Senior Lecturer in Immunology and Bioscience

Room 240, Medical Science 2, Hobart CBD Campuses

+61 3 6226 4681 (phone)

+61 3 6226 4682 (fax)

Bruce.Lyons@utas.edu.au

The distressing facts about devil facial tumour disease (DFTD) have become well known in recent years, with the Tasmanian devil population declining by more than 80 per cent since this rare, transmissible cancer was first detected in the 1990s. Equally dramatic, however, has been the response to save this iconic marsupial.

DFTD vaccine: devil is in the detail

Dr Bruce Lyons, a senior lecturer in Immunology in the UTAS School of Medicine, is a leader of the group that is working on a vaccine to protect Tasmanian devils from this almost invariably-fatal cancer. The team has been able to produce in the laboratory an immune response in devils to DFTD, and also found that the devil’s immune system can, in certain circumstances, eradicate the tumours. The next step is to ‘connect the dots’ to hopefully produce a single-shot vaccine.

‘We’ve still got a bit of a way to get there,’ Dr Lyons said, ‘but compared to the history of tumour immunology in human work, the achievements with devils in the last 10 years are outstanding.’

Switching on the immune system

DFTD is passed from devil to devil through contact, such as the biting associated with mating and fighting. It produces large tumours, mostly around the face and neck, which lead to death from starvation and the breakdown of bodily functions.

While these tumours are confronting to witness, it is their ability to become invisible to the devil’s immune system that makes them so deadly. All transplanted tissue will normally be rejected as different by its host because of surface molecules called MHC, but the DFTD tumours have sneakily worked out a way to shut off these MHC molecules.

To counter this, scientists have developed methods to force the tumours to again produce these MHC molecules – and it was live cancer cells, treated to show MHC, that were used as the basis for immunotherapy by Dr Lyons and the DFTD immunology group.

‘When we injected those treated cells just next to the tumour, we found that the tumour would just melt away,’ Dr Lyons said. ‘In three out of the six devils, the tumour completely disappeared. So we know that the immune system can get rid of the tumour, and our current model of the immunisation candidate is also using DFTD cells that have been treated to express those MHC molecules.’

The challenge of the puzzle

Before returning to Tasmania and accepting a position at UTAS, Dr Lyons completed post-doctoral work in Scotland as well as at the John Curtin School of Medical Research in the ACT, and at the Institute of Medical and Veterinary Science in Adelaide. This was followed by industry work on the development of vaccines, providing a natural link not only to his research on the devil vaccine but also his other area of interest, which is the allergy to jack jumper ants.

‘Immunology was completely new as a standalone course when I began to study it as an undergraduate, and that really attracted me,’ Dr Lyons said. ‘Of course immunology as we know it has been practised since the late 1700s with the development of the smallpox vaccine, but it was all empirical – nobody had a clue how it worked. It was a detective story waiting to be investigated.

‘When I think back on the work we did in those early years of immunology in the mid ‘80s to early 2000s, I realise we got the chance to fill in some major holes in our understanding. I think that has been my driving force. This is probably true for many scientists in that it’s the puzzle that provides the challenge that keeps you going. It’s like being a detective in that we’re trying to figure out what’s going on. That investigative drive is what keeps us scientists plugging away.’

Dr Lyons is a senior lecturer in the School of Medicine. His career spans basic and applied immunology in the fields of leukaemia research, leukocyte trafficking, vaccine development and tumour immunology, with a particular interest in applied flow cytometry methodology.

Biography

Dr Lyons' PhD in Immunology from the University of Adelaide (1988) was on the development of monoclonal antibodies to human myeloid differentiation antigens. After a short period examining cytokine control of histamine release by basophils (Human Immunology, IMVS, Adelaide), his postdoctoral studies included apoptosis and chronic lymphocytic leukaemia models (University of Edinburgh), lymphocyte migration to spleen (JCSMR, ANU and University of Tasmania) and off-target immunological effects of new small molecule targeted therapies for chronic myeloid leukaemia (Haematology, IMVS Adelaide). After 2 years in a biotech start up investigating new carbohydrate adjuvants (Vaxine, Flinders University, Adelaide) Dr Lyons returned to the University of Tasmania to take up a teaching only senior lectureship in 2008, before being appointed to a teaching/research senior lectureship in 2010.

Career summary

Qualifications

  • PhD, University of Adelaide, Australia, 1988. Human myeloid differentiation antigens
  • BSc (Upper 2nd Class Hons), University of Adelaide, Australia, 1983. Preparation of membrane antigeens from normal and leukaemic cells

Memberships

Professional practice

  • Australasian Society for Immunology

Administrative expertise

  • Research project management
  • Graduate research coordination
  • Honours program coordination
  • Management of a central flow cytometry and imaging facility

Teaching

Immunology, unit design (Immunology), flow cytometric applications

Teaching responsibility

View more on AssocProf Bruce Lyons in WARP

Expertise

  • Specialised flow cytometric techniques to examine cell division, apoptosis and adhesion
  • Small laboratory animal models of immune processes
  • Monoclonal antibody development

Research Themes

Dr Lyons' research interests are tumour immunology of Devil Facial Tumour Disease (DFTD), immune regulation and allergy responses to pathogens and vaccine development, modulation of immunity by off-target activity of small molecule cancer therapies and the development and application of flow cytometric techniques to complex immunological questions.

He is currently a member of the Devil Facial Tumour Disease immunology group headed by Professor Greg Woods (MRIT)  and collaborates with the Jack Jumper Allergy program in the RHH (Professor Simon Brown and Mr Troy Wanandy).

Collaboration

Bruce's collaborations locally include the Royal Hobart Hospital, and he collaborates with researchers at the University of South Australia, and through the Devil Immunology group researchers in Melbourne, Cambridge and Southampton.

Current projects

Currently involved in the development of immune approaches to combatting Devil Facial Tumour Disease, and analysis of T cell responses in Jack Jumper Ant Venom allergy.

Fields of Research

  • Cellular Immunology (110704)
  • Animal Immunology (060804)
  • Immunology (110799)
  • Veterinary Immunology (070705)
  • Haematology (110202)
  • Tumour Immunology (110709)
  • Medical Bacteriology (110801)
  • Humoural Immunology and Immunochemistry (110705)
  • Clinical Sciences (110399)
  • Molecular Targets (111207)
  • Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies) (110702)
  • Zoology (060899)
  • Respiratory Diseases (110203)
  • Conservation and Biodiversity (050202)
  • Host-Parasite Interactions (060307)
  • Proteomics and Intermolecular Interactions (excl. Medical Proteomics) (060109)
  • Cell Development, Proliferation and Death (060103)
  • Allergy (110701)
  • Veterinary Epidemiology (070704)
  • Aquaculture (070401)
  • Innate Immunity (110707)
  • Medical Parasitology (110803)
  • Ecosystem Function (050102)
  • Animal Cell and Molecular Biology (060802)
  • Immunogenetics (incl. Genetic Immunology) (110706)
  • Veterinary Microbiology (excl. Virology) (070707)
  • Autoimmunity (110703)
  • Veterinary Diagnosis and Diagnostics (070703)
  • Biological Oceanography (040501)
  • Veterinary Surgery (070711)
  • Gene Expression (incl. Microarray and other genome-wide approaches) (060405)
  • Transplantation Immunology (110708)
  • Animal Structure and Function (060807)
  • Environmental Monitoring (050206)
  • Behavioural Ecology (060201)

Research Objectives

  • Immune System and Allergy (920108)
  • Health (929999)
  • Flora, Fauna and Biodiversity at Regional or Larger Scales (960805)
  • Expanding Knowledge in the Environmental Sciences (970105)
  • Expanding Knowledge in the Biological Sciences (970106)
  • Cancer and Related Disorders (920102)
  • Expanding Knowledge in the Agricultural and Veterinary Sciences (970107)
  • Infectious Diseases (920109)
  • Blood Disorders (920101)
  • Expanding Knowledge in the Medical and Health Sciences (970111)
  • Respiratory System and Diseases (incl. Asthma) (920115)
  • Fisheries - Aquaculture (830199)
  • Control of Pests, Diseases and Exotic Species at Regional or Larger Scales (960405)
  • Digestive System Disorders (920105)
  • Nervous System and Disorders (920111)

Publications

Bruce has over 50 publications, many of which are in top ranked international journals. On average they have been cited around 100 times, generating an H-index of 26. His highest cited paper describes a flow based method for determining cell division history used which has been cited over 1500 times.

Bruce is currently an editorial Board member of The Journal of Immunological Methods.

Total publications

82

Journal Article

(66 outputs)
YearCitationAltmetrics
2019Li X, Darby J, Lyons AB, Woods GM, Korner H, 'TNF may negatively regulate phagocytosis of Devil Facial Tumour disease cells by activated macrophages', Immunological Investigations pp. 1-13. ISSN 0882-0139 (2019) [Refereed Article]

DOI: 10.1080/08820139.2018.1515222 [eCite] [Details]

Citations: Scopus - 2Web of Science - 3

Co-authors: Darby J; Woods GM; Korner H

Tweet

2019Ong CEB, Lyons AB, Woods GM, Flies AS, 'Inducible IFN-γ expression for MHC-I upregulation in devil facial tumor cells', Frontiers in Immunology, 9 Article 3117. ISSN 1664-3224 (2019) [Refereed Article]

DOI: 10.3389/fimmu.2018.03117 [eCite] [Details]

Co-authors: Woods GM; Flies AS

Tweet

2019Thaver S, Bennett EJ, Foa L, Richards SM, Lyons AB, et al., 'Pregnancy protects against the pro-inflammatory respiratory responses induced by particulate matter exposure', Chemosphere, 225 pp. 796-802. ISSN 0045-6535 (2019) [Refereed Article]

DOI: 10.1016/j.chemosphere.2019.03.088 [eCite] [Details]

Co-authors: Thaver S; Bennett EJ; Foa L; Richards SM; Zosky GR

Tweet

2019Wang X, Iyer A, Lyons AB, Korner H, Wei W, 'Emerging roles for G-protein coupled receptors in development and activation of macrophages', Frontiers in Immunology, 10 Article 2031. ISSN 1664-3224 (2019) [Refereed Article]

DOI: 10.3389/fimmu.2019.02031 [eCite] [Details]

Co-authors: Korner H

Tweet

2019Patchett AL, Coorens THH, Darby J, Wilson R, McKay MJ, et al., 'Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus harrisii)', Cellular and Molecular Life Sciences pp. 1-12. ISSN 1420-682X (2019) [Refereed Article]

DOI: 10.1007/s00018-019-03259-2 [eCite] [Details]

Co-authors: Patchett AL; Darby J; Wilson R; Pye RJ; Flies AS; Woods GM; Tovar C

Tweet

2018Hu S, Marshall C, Darby J, Wei W, Lyons AB, et al., 'Absence of tumor necrosis factor supports alternative activation of macrophages in the liver after infection with Leishmania major', Frontiers in Immunology, 9 Article 1. ISSN 1664-3224 (2018) [Refereed Article]

DOI: 10.3389/fimmu.2018.00001 [eCite] [Details]

Citations: Scopus - 2Web of Science - 3

Co-authors: Hu S; Marshall C; Darby J; Korner H

Tweet

2018Patchett AL, Wilson R, Charlesworth JC, Corcoran LM, Papenfuss AT, et al., 'Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells', OncoTarget, 9, (22) pp. 15895-15914. ISSN 1949-2553 (2018) [Refereed Article]

DOI: 10.18632/oncotarget.24634 [eCite] [Details]

Citations: Scopus - 2

Co-authors: Patchett AL; Wilson R; Charlesworth JC; Woods GM; Tovar C

Tweet

2018Tovar C, Patchett AL, Kim V, Wilson R, Darby J, et al., 'Heat shock proteins expressed in the marsupial Tasmanian devil are potential antigenic candidates in a vaccine against devil facial tumour disease', PLoS ONE, 13, (4) Article e0196469. ISSN 1932-6203 (2018) [Refereed Article]

DOI: 10.1371/journal.pone.0196469 [eCite] [Details]

Citations: Scopus - 1Web of Science - 1

Co-authors: Tovar C; Patchett AL; Wilson R; Darby J; Woods GM

Tweet

2018Woods GM, Fox S, Flies A, Tovar CD, Jones M, et al., 'Two decades of the impact of Tasmanian Devil Facial Tumour Disease (DFTD)', Integrative and Comparative Biology, 58, (6) pp. 1043-1054. ISSN 1540-7063 (2018) [Refereed Article]

DOI: 10.1093/icb/icy118 [eCite] [Details]

Co-authors: Woods GM; Flies A; Tovar CD; Jones M; Hamede R; Bettiol S

Tweet

2018Chen L, Bennett E, Wheeler AJ, Lyons AB, Woods GM, et al., 'Maternal exposure to particulate matter alters early post-natal lung function and immune cell development', Environmental Research, 164 pp. 625-635. ISSN 0013-9351 (2018) [Refereed Article]

DOI: 10.1016/j.envres.2018.03.029 [eCite] [Details]

Citations: Scopus - 2Web of Science - 1

Co-authors: Chen L; Bennett E; Wheeler AJ; Woods GM; Johnston F; Zosky GR

Tweet

2018Pye R, Patchett A, McLennan E, Thomson R, Carver S, et al., 'Immunization strategies producing a humoral IgG immune response against devil facial tumor disease in the majority of Tasmanian devils destined for wild release', Frontiers in Immunology, 9 Article 259. ISSN 1664-3224 (2018) [Refereed Article]

DOI: 10.3389/fimmu.2018.00259 [eCite] [Details]

Citations: Scopus - 7Web of Science - 9

Co-authors: Pye R; Patchett A; Carver S; Kreiss A; Woods GM

Tweet

2017Li X, Lyons AB, Woods GM, Korner H, 'The absence of TNF permits myeloid Arginase 1 expression in experimental L. monocytogenes infection', Immunobiology, 222, (8-9) pp. 913-917. ISSN 0171-2985 (2017) [Refereed Article]

DOI: 10.1016/j.imbio.2017.05.012 [eCite] [Details]

Citations: Scopus - 5Web of Science - 5

Co-authors: Woods GM; Korner H

Tweet

2017Patchett AL, Tovar C, Corcoran LM, Lyons AB, Woods GM, 'The toll-like receptor ligands Hiltonol® (polyICLC) and imiquimod effectively activate antigen-specific immune responses in Tasmanian devils (Sarcophilus harrisii)', Developmental and Comparative Immunology, 76 pp. 352-360. ISSN 0145-305X (2017) [Refereed Article]

DOI: 10.1016/j.dci.2017.07.004 [eCite] [Details]

Citations: Scopus - 5Web of Science - 6

Co-authors: Patchett AL; Tovar C; Woods GM

Tweet

2017Tovar C, Pye RJ, Kreiss A, Cheng Y, Brown GK, et al., 'Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils', Scientific Reports, 7 Article 43827. ISSN 2045-2322 (2017) [Refereed Article]

DOI: 10.1038/srep43827 [eCite] [Details]

Citations: Scopus - 20Web of Science - 21

Co-authors: Tovar C; Pye RJ; Kreiss A; Brown GK; Darby J; Malley RC; Woods GM

Tweet

2017Flies AS, Blackburn NB, Lyons AB, Hayball JD, Woods GM, 'Comparative analysis of immune checkpoint molecules and their potential role in the transmissible Tasmanian Devil facial tumor disease', Frontiers in Immunology, 8 Article 513. ISSN 1664-3224 (2017) [Refereed Article]

DOI: 10.3389/fimmu.2017.00513 [eCite] [Details]

Citations: Scopus - 4Web of Science - 5

Co-authors: Flies AS; Blackburn NB; Woods GM

Tweet

2017Latham RD, Gell DA, Fairbairn RL, Lyons AB, Shukla SD, et al., 'An isolate of Haemophilus haemolyticus produces a bacteriocin-like substance that inhibits the growth of nontypeable Haemophilus influenzae', International Journal of Antimicrobial Agents, 49, (4) pp. 503-506. ISSN 0924-8579 (2017) [Refereed Article]

DOI: 10.1016/j.ijantimicag.2016.12.010 [eCite] [Details]

Citations: Scopus - 3Web of Science - 3

Co-authors: Latham RD; Gell DA; Shukla SD; Tristram SG

Tweet

2016Flies AS, Lyons AB, Corcoran LM, Papenfuss AT, Murphy JM, et al., 'PD-L1 is not constitutively expressed on Tasmanian devil facial tumor cells but is strongly upregulated in response to IFN-γ and can be expressed in the tumor microenvironment', Frontiers in Immunology, 7 Article 581. ISSN 1664-3224 (2016) [Refereed Article]

DOI: 10.3389/fimmu.2016.00581 [eCite] [Details]

Citations: Scopus - 11Web of Science - 11

Co-authors: Flies AS; Woods GM

Tweet

2016Patchett AL, Darby JM, Tovar C, Lyons AB, Woods GM, 'The immunomodulatory small molecule imiquimod induces apoptosis in devil facial tumour cell lines', PL o S One, 11, (12) Article e0168068. ISSN 1932-6203 (2016) [Refereed Article]

DOI: 10.1371/journal.pone.0168068 [eCite] [Details]

Citations: Scopus - 5Web of Science - 5

Co-authors: Patchett AL; Darby JM; Tovar C; Woods GM

Tweet

2016Brown GK, Tovar C, Cooray AA, Kreiss A, Darby J, et al., 'Mitogen activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells', Immunology and Cell Biology, 94, (7) pp. 673-679. ISSN 0818-9641 (2016) [Refereed Article]

DOI: 10.1038/icb.2016.38 [eCite] [Details]

Citations: Scopus - 12Web of Science - 12

Co-authors: Brown GK; Tovar C; Cooray AA; Kreiss A; Darby J; Bettiol SS; Woods GM

Tweet

2016Pye RJ, Hamede R, Siddle HV, Caldwell A, Knowles GW, et al., 'Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils', Biology Letters, 12, (10) Article 20160553. ISSN 1744-9561 (2016) [Refereed Article]

DOI: 10.1098/rsbl.2016.0553 [eCite] [Details]

Citations: Scopus - 27Web of Science - 30

Co-authors: Pye RJ; Hamede R; Kreiss A; Jones ME; Woods GM

Tweet

2015Kreiss A, Brown GK, Tovar C, Lyons AB, Woods GM, 'Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations', Vaccine, 33, (26) pp. 3016-3025. ISSN 0264-410X (2015) [Refereed Article]

DOI: 10.1016/j.vaccine.2015.01.039 [eCite] [Details]

Citations: Scopus - 33Web of Science - 31

Co-authors: Kreiss A; Brown GK; Tovar C; Woods GM

Tweet

2015Pye RJ, Pemberton D, Tovar C, Tubio JM, Dun KA, et al., 'A second transmissible cancer in Tasmanian devils', Proceedings of the National Academy of Sciences, 113, (2) pp. 374-379. ISSN 0027-8424 (2015) [Refereed Article]

DOI: 10.1073/pnas.1519691113 [eCite] [Details]

Citations: Scopus - 64Web of Science - 64

Co-authors: Pye RJ; Tovar C; Darby J; Kreiss A; Woods GM

Tweet

2015Woods GM, Howson LJ, Brown GK, Tovar C, Kreiss A, et al., 'Immunology of a transmissible cancer spreading among Tasmanian devils', Journal of Immunology, 195, (1) pp. 23-29. ISSN 0022-1767 (2015) [Refereed Article]

DOI: 10.4049/jimmunol.1500131 [eCite] [Details]

Citations: Scopus - 15Web of Science - 15

Co-authors: Woods GM; Howson LJ; Brown GK; Tovar C; Kreiss A

Tweet

2015Patchett AL, Latham R, Brettingham-Moore KH, Tovar C, Lyons AB, et al., 'Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil', Developmental and Comparative Immunology, 53 pp. 123-133. ISSN 0145-305X (2015) [Refereed Article]

DOI: 10.1016/j.dci.2015.07.003 [eCite] [Details]

Citations: Scopus - 11Web of Science - 10

Co-authors: Patchett AL; Latham R; Brettingham-Moore KH; Tovar C; Woods GM

Tweet

2012Quah BJC, Lyons AB, Parish CR, 'The use of CFSE-like dyes for measuring lymphocyte proliferation: experimental considerations and biological variables', Mathematical Modelling of Natural Phenomena, 7, (5) pp. 53 - 64. ISSN 0973-5348 (2012) [Refereed Article]

DOI: 10.1051/mmnp/20127505 [eCite] [Details]

Citations: Scopus - 1Web of Science - 1

Tweet

2012Blake SJ, Hughes TP, Lyons AB, 'Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A', Experimental Hematology, 40, (8) pp. 612 - 621. ISSN 0301-472X (2012) [Refereed Article]

DOI: 10.1016/j.exphem.2012.04.003 [eCite] [Details]

Citations: Scopus - 12Web of Science - 9

Tweet

2011Brown GK, Kreiss A, Lyons AB, Woods GM, 'Natural Killer Cell Mediated Cytotoxic Responses in the Tasmanian Devil', PL o S One , 6, (9) Article e24475. ISSN 1932-6203 (2011) [Refereed Article]

DOI: 10.1371/journal.pone.0024475 [eCite] [Details]

Citations: Scopus - 28Web of Science - 27

Co-authors: Brown GK; Kreiss A; Woods GM

Tweet

2009Blake SJ, Lyons AB, Hughes TP, 'Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro', Journal of Cellular and Molecular Medicine, 13, (3) pp. 599-601. ISSN 1582-1838 (2009) [Letter or Note in Journal]

DOI: 10.1111/j.1582-4934.2009.00500.x [eCite] [Details]

Citations: Scopus - 22

Tweet

2009Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, et al., 'Dasatinib inhibits recombinant viral antigen-specific murine CD4(+) and CD8(+) T-cell responses and NK-cell cytolytic activity in vitro and in vivo', Experimental Hematology, 37, (2) pp. 256-265. ISSN 0301-472X (2009) [Refereed Article]

DOI: 10.1016/j.exphem.2008.09.013 [eCite] [Details]

Citations: Scopus - 49Web of Science - 47

Tweet

2008Blake S, Hughes TP, Mayrhofer G, Lyons AB, 'The Src/Abl kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro', Clinical Immunology, 127, (3) pp. 330-339. ISSN 1521-6616 (2008) [Refereed Article]

DOI: 10.1016/j.clim.2008.02.006 [eCite] [Details]

Citations: Scopus - 74Web of Science - 64

Tweet

2008Blake S, Lyons AB, Fraser C, Hayball JD, Hughes TP, 'Dasatinib suppresses in vitro natural killer cell cytotoxicity', Blood, 111, (8) pp. 4415-4416. ISSN 0006-4971 (2008) [Refereed Article]

DOI: 10.1182/blood-2008-02-138701 [eCite] [Details]

Citations: Scopus - 59Web of Science - 59

Tweet

2008Diener KR, Moldenhauer L, Lyons AB, Brown MP, Hayball JD, 'Human Flt-3-ligand-mobilized dendritic cells require additional activation to drive effective immune responses', Experimental Hematology, 36, (1) pp. 51-60. ISSN 0301-472X (2008) [Refereed Article]

DOI: 10.1016/j.exphem.2007.08.024 [eCite] [Details]

Citations: Scopus - 14Web of Science - 13

Tweet

2007Petrovsky N, Heinzel S, Honda Y, Lyons AB, 'New-age adjuvants: friend or foe?', Biopharm International-The Applied Technologies of Biopharmaceutical Development, 20, (8) pp. A24-A33. ISSN 1542-166X (2007) [Refereed Article]

[eCite] [Details]

Citations: Scopus - 13Web of Science - 4

2007Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, et al., 'Resistance to c-KIT kinase inhibitors conferred by V654A mutation', Molecular Cancer Therapeutics, 6, (3) pp. 1159-1166. ISSN 1535-7163 (2007) [Refereed Article]

DOI: 10.1158/1535-7163.MCT-06-0641 [eCite] [Details]

Citations: Scopus - 61Web of Science - 60

Tweet

2006Lyons AB, Watkins M, Simpson CC, Muller HK, 'Modulation of lymphocyte migration to the murine spleen after macrophage phagocytosis of blood-borne particulate material', Immunological Investigations: A Journal of Molecular and Cellular Immunology, 35, (1) pp. 75-92. ISSN 0882-0139 (2006) [Refereed Article]

DOI: 10.1080/08820130500496811 [eCite] [Details]

Citations: Scopus - 3Web of Science - 3

Co-authors: Muller HK

Tweet

2005Dewar AL, Cambareri AC, Zannettino ACW, Doherty KV, Hughes TP, et al., 'Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib', Blood, 105, (8) pp. 3127-3132. ISSN 0006-4971 (2005) [Refereed Article]

DOI: 10.1182/blood-2004-10-3967 [eCite] [Details]

Citations: Scopus - 234Web of Science - 220

Tweet

2005Dewar AL, Zannettino ACW, Hughes TP, Lyons AB, 'Inhibition of c-fms by imatinib: expanding the spectrum of treatment', Cell Cycle, 4, (7) pp. 38-40. ISSN 1538-4101 (2005) [Refereed Article]

DOI: 10.4161/cc.4.7.1788 [eCite] [Details]

Citations: Scopus - 44Web of Science - 43

Tweet

2005Morrison RN, Lyons AB, Nowak BF, Hayball JD, 'Assessment of snapper (Pagrus auratus) natural IgM binding to bromelain treated sheep erythrocytes', Fish and Shellfish Immunology, 18 pp. 91-99. ISSN 1050-4648 (2005) [Refereed Article]

DOI: 10.1016/j.fsi.2004.06.006 [eCite] [Details]

Citations: Scopus - 4Web of Science - 4

Tweet

2005White DL, Saunders VA, Lyons AB, Branford S, Hughes TP, 'In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML', Blood, 106, (7) pp. 2520-2526. ISSN 0006-4971 (2005) [Refereed Article]

DOI: 10.1182/blood-2005-03-1103 [eCite] [Details]

Citations: Scopus - 109Web of Science - 97

Tweet

2005Dewar AL, Doherty KV, Hughes TP, Lyons AB, 'Imatinib inhibits the functional capacity of cultured human monocytes', Immunology and Cell Biology, 83, (1) pp. 48-56. ISSN 0818-9641 (2005) [Refereed Article]

DOI: 10.1111/j.1440-1711.2004.01296.x [eCite] [Details]

Citations: Scopus - 35Web of Science - 35

Tweet

2004Morrison RN, Lyons AB, Nowak BF, Hayball JD, 'Snapper (Pagrus auratus) leucocyte proliferation is synergistically enhanced by simultaneous stimulation with LPS and PHA', Fish & Shellfish Immunology, 16, (3) pp. 307-319. ISSN 1050-4648 (2004) [Refereed Article]

DOI: 10.1016/S1050-4648(03)00112-8 [eCite] [Details]

Citations: Scopus - 14Web of Science - 10

Co-authors: Morrison RN; Nowak BF

Tweet

2003Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB, 'Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors', Leukemia, 17, (9) pp. 1713-1721. ISSN 0887-6924 (2003) [Refereed Article]

DOI: 10.1038/sj.leu.2403071 [eCite] [Details]

Citations: Scopus - 51Web of Science - 47

Co-authors: Doherty KV

Tweet

2002Wilkinson R, Lyons AB, Roberts D, Wong M-X, Bartley PA, et al., 'Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) acts as a regulator of B-cell development, B-cell antigen receptor (BCR)-mediated activation, and autoimmune disease', Blood, 100, (1) pp. 184-193. ISSN 0006-4971 (2002) [Refereed Article]

DOI: 10.1182/blood-2002-01-0027 [eCite] [Details]

Citations: Scopus - 86Web of Science - 74

Tweet

2001Dewar AL, Doherty KV, Woods GM, Lyons AB, Muller HK, 'Acquisition of immune function during the development of the Langerhans cell network in neonatal mice', Immunology, 103, (1) pp. 61-69. ISSN 0019-2805 (2001) [Refereed Article]

DOI: 10.1046/j.1365-2567.2001.01221.x [eCite] [Details]

Citations: Scopus - 31Web of Science - 31

Co-authors: Doherty KV; Woods GM; Muller HK

Tweet

2001Lyons AB, Hasbold J, Hodgkin PD, 'Chapter 17 Flow cytometric analysis of cell division history using dilution of Carboxyfluorescein Diacetate Succinimidyl Ester, a stably integrated fluorescent probe', Methods in Cell Biology, 63 (Part A) pp. 375-398. ISSN 0091-679X (2001) [Refereed Article]

DOI: 10.1016/S0091-679X(01)63021-8 [eCite] [Details]

Citations: Web of Science - 92

Tweet

2000Lyons AB, 'Analysing Cell Division in vivo Using Flow Cytometric Measurement of CFSE Dye Dilution', Journal of Immunological Methods, 243, (1-2) pp. 147-154. ISSN 0022-1759 (2000) [Refereed Article]

DOI: 10.1016/S0022-1759(00)00231-3 [eCite] [Details]

Citations: Scopus - 519Web of Science - 500

Tweet

1999Lyons AB, 'Divided we stand: Tracking cell proliferation with carboxyfluorescein diacetate succinimidyl ester', Immunology and Cell Biology, 77, (6) pp. 509-515. ISSN 0818-9641 (1999) [Refereed Article]

DOI: 10.1046/j.1440-1711.1999.00864.x [eCite] [Details]

Citations: Scopus - 120Web of Science - 113

Tweet

1998Hasbold J, Lyons AB, Kehry MR, Hodgkin PD, 'Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4', European Journal of Immunology, 28, (3) pp. 1040-1051. ISSN 0014-2980 (1998) [Refereed Article]

DOI: 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.3.CO;2-0 [eCite] [Details]

Citations: Scopus - 157Web of Science - 154

Tweet

1998Lyons AB, Cooper SJ, Cole SR, Ashman LK, 'Human myeloid differentiation antigens identified by monoclonal antibodies to the myelomonocytic leukemia cell line RC-2A', Pathology, 20, (2) pp. 137-146. ISSN 0031-3025 (1998) [Refereed Article]

DOI: 10.3109/00313028809066624 [eCite] [Details]

Citations: Scopus - 15Web of Science - 17

Tweet

1997Hodgkin PD, Chin SH, Bartell G, Mamchak A, Doherty K, et al., 'The importance of efficacy and partial agonism in evaluating models of B lymphocyte activation', International Review of Immunology, 15, (1-2) pp. 101-127. ISSN 0883-0185 (1997) [Refereed Article]

DOI: 10.3109/08830189709068173 [eCite] [Details]

Citations: Scopus - 17

Tweet

1997Lyons AB, 'Pertussis toxin pretreatment alters the in vivo cell division behaviour and survival of B lymphocytes after intravenous transfer', Immunology and Cell Biology, 75, (1) pp. 7-12. ISSN 0818-9641 (1997) [Refereed Article]

DOI: 10.1038/icb.1997.2 [eCite] [Details]

Citations: Scopus - 18Web of Science - 16

Tweet

1996Bradbury MG, Doherty KV, Parish CR, Lyons AB, 'The immunosuppressive compound 2-acetyl-4-tetrahydroxybutyl imidazole inhibits the allogeneic mixed lymphocyte reaction by sequestration of a recirculating subpopulation of T cells', Immunology, 87, (1) pp. 80-85. ISSN 0019-2805 (1996) [Refereed Article]

[eCite] [Details]

Citations: Web of Science - 8

1996Hodgkin PD, Lee JH, Lyons AB, 'B cell differentiation and isotype switching is related to division cycle number', Journal of Experimental Medicine, 184, (1) pp. 277-281. ISSN 0022-1007 (1996) [Refereed Article]

DOI: 10.1084/jem.184.1.277 [eCite] [Details]

Citations: Scopus - 298Web of Science - 291

Tweet

1996Lyons AB, 'Fundamental Immunology - Book Review', Immunology and Cell Biology, 73, (1) pp. 98. ISSN 0818-9641 (1996) [Letter or Note in Journal]

[eCite] [Details]

1996Lyons AB, 'Essential Immunology - Book Review', Immunology and Cell Biology, 73, (2) pp. 186-187. ISSN 0818-9641 (1996) [Letter or Note in Journal]

[eCite] [Details]

1996Fulcher DA, Lyons AB, Korn SL, Cook MC, Koleda C, et al., 'The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help', Journal of Experimental Medicine, 183, (5) pp. 2313-2328. ISSN 0022-1007 (1996) [Refereed Article]

DOI: 10.1084/jem.183.5.2313 [eCite] [Details]

Citations: Scopus - 224Web of Science - 214

Tweet

1995Lyons AB, Parish CR, 'Are murine marginal zone macrophages the splenic white pulp analog of high endothelial venules?', European Journal of Immunology, 25, (11) pp. 3165-3172. ISSN 0014-2980 (1995) [Refereed Article]

DOI: 10.1002/eji.1830251127 [eCite] [Details]

Citations: Scopus - 60Web of Science - 58

Tweet

1994Lyons AB, Parish CR, 'Determination of lymphocyte division by flow cytometry', Journal of Immunological Methods, 171, (1) pp. 131-137. ISSN 0022-1759 (1994) [Refereed Article]

DOI: 10.1016/0022-1759(94)90236-4 [eCite] [Details]

Citations: Scopus - 1390Web of Science - 1340

Tweet

1993Deckers CL, Lyons AB, Samuel K, Sanderson A, Maddy AH, 'Alternative pathways of apoptosis induced by methylprednisolone and valinomycin analyzed by flow cytometry', Experimental Cell Research, 208, (2) pp. 362-370. ISSN 0014-4827 (1993) [Refereed Article]

DOI: 10.1006/excr.1993.1257 [eCite] [Details]

Citations: Scopus - 42Web of Science - 44

Tweet

1992Lyons AB, Samuel K, Sanderson A, Maddy AH, 'Simultaneous analysis of immunophenotype and apoptosis of murine thymocytes by single laser flow cytometry', Cytometry. Part A, 13, (8) pp. 809-821. ISSN 1552-4922 (1992) [Refereed Article]

DOI: 10.1002/cyto.990130803 [eCite] [Details]

Citations: Scopus - 96Web of Science - 99

Tweet

1991Maddy A, Lyons AB, Wu ZW, Taylor H, Sanderson A, et al., 'Discrete subpopulations, defined by CD45 isoforms, coexist within the leukaemic cells of B-chronic lymphocytic leukaemia patients', Leukemia Research, 15, (9) pp. 791-799. ISSN 0145-2126 (1991) [Refereed Article]

DOI: 10.1016/0145-2126(91)90463-4 [eCite] [Details]

Citations: Scopus - 4Web of Science - 4

Tweet

1990Lopez AF, Eglinton JM, Lyons AB, Tapley PM, To LB, et al., 'Human interleukin-3 inhibits the binding of granulocyte-macrophage colony-stimulating factor and interleukin-5 to basophils and strongly enhances their functional activity', Journal of Cellular Physiology, 145, (1) pp. 69-77. ISSN 0021-9541 (1990) [Refereed Article]

DOI: 10.1002/jcp.1041450111 [eCite] [Details]

Citations: Scopus - 78Web of Science - 122

Tweet

1990Lopez AF, Lyons AB, Eglnton JM, Park LS, Clark SC, et al., 'Specific binding of human interleukin-3 and granulocyte-macrophage colony-stimulating factor to human basophils', The Journal of Allergy and Clinical Immunology, 85, (1) pp. 99-102. ISSN 0091-6749 (1990) [Refereed Article]

DOI: 10.1016/0091-6749(90)90229-W [eCite] [Details]

Citations: Scopus - 27Web of Science - 32

Tweet

1988Cambareri AC, Ashman LK, Cole SR, Lyons AB, 'A monoclonal antibody to a human mast cell/myeloid leukaemia-specific antigen binds to normal haemopoietic progenitor cells and inhibits colony formation in vitro', Leukemia Research, 12, (11-12) pp. 929-939. ISSN 0145-2126 (1988) [Refereed Article]

DOI: 10.1016/0145-2126(88)90021-5 [eCite] [Details]

Citations: Scopus - 23Web of Science - 27

Tweet

1988Lyons AB, Ashman LK, 'The effect of recombinant cytokines on the proliferative potential and phenotype of cells of the human myelomonocytic leukaemia line, RC-2A', Leukemia Research, 12, (8) pp. 659-666. ISSN 0145-2126 (1988) [Refereed Article]

DOI: 10.1016/0145-2126(88)90100-2 [eCite] [Details]

Citations: Scopus - 4Web of Science - 3

Tweet

1987Lyons AB, Ashman LK, 'Studies on the differentiation of the human myelomonocytic cell line RC-2A in response to lymphocyte-derived factors', Leukemia Research, 11, (9) pp. 797-805. ISSN 0145-2126 (1987) [Refereed Article]

DOI: 10.1016/0145-2126(87)90064-6 [eCite] [Details]

Citations: Scopus - 3Web of Science - 3

Tweet

Chapter in Book

(2 outputs)
YearCitationAltmetrics
2013Lyons AB, Blake SJ, Doherty KV, 'Flow cytometric analysis of cell division by dilution of CFSE and related dyes', Current Protocols in Cytometry, John Wiley & Sons, JP Robinson et al (ed), Hoboken, NJ, pp. 9.11.1-9.11.12. ISBN 9780471142959 (2013) [Research Book Chapter]

DOI: 10.1002/0471142956.cy0911s64 [eCite] [Details]

Citations: Scopus - 36

Co-authors: Doherty KV

Tweet

1998Lyons AB, Doherty KV, 'Flow cytometric analysis of cell division by dye dilution', Current Protocols in Cytometry, John Wiley and Sons, New York, J. Paul Robinson (ed), New York, pp. 9.11.1-9.11.9. ISBN 0-471-16131-4 (1998) [Research Book Chapter]

PMID: 18770808 [eCite] [Details]

Citations: Scopus - 25

Co-authors: Doherty KV

Tweet

Review

(1 outputs)
YearCitationAltmetrics
2013Lee AYS, Eri RD, Lyons AB, Grimm MC, Korner H, 'CC chemokine ligand 20 and its cognate receptor CCR6 in mucosal T cell immunology and inflammatory bowel disease: odd couple or axis of evil?', Frontiers in Immunology, 4, (194) pp. 1-7. ISSN 1664-3224 (2013) [Substantial Review]

DOI: 10.3389/fimmu.2013.00194 [eCite] [Details]

Citations: Scopus - 41Web of Science - 46

Co-authors: Lee AYS; Eri RD; Korner H

Tweet

Conference Publication

(11 outputs)
YearCitationAltmetrics
2017Karu N, Patchett AL, Wilson RR, Hamede Ross RK, Jones Menna, et al., 'Application of metabolomics and proteomics for biomarker discovery and development of therapies for the transmissible cancer, Tasmanian Devil Facial Tumour Disease', February 2nd-5th 2017, Lorne, VIC, pp. Page 22. (2017) [Conference Edited]

[eCite] [Details]

Co-authors: Karu N; Patchett AL; Wilson RR; Hamede Ross RK; Jones Menna; Woods GM

1999Lyons AB, Simpson CC, 'B lymphocyte migration to the spleen increases after Phagocytosis: A role for the chemokine BLC', 38th National Scientific Conference of the Australian Society for Medical Research, 27-29/11/1999, Leura, NSW, pp. poster 1-11. (1999) [Conference Extract]

[eCite] [Details]

Co-authors: Simpson CC

1998Hughes JN, Lyons AB, 'Isotype switching in murine B1 cells and its relationship to cell division', 37th Annual Meeting of the Australian Society for Medical Research, 22-25 November, Hobart, Tasmania, pp. 70. (1998) [Conference Extract]

[eCite] [Details]

1998Lyons AB, 'Modification of the Immune Response', 37th National Scientific Conference of the Australian Society for Immunology, 22-25 November, Hobart, Tasmania, pp. Symposium 5. (1998) [Chair National Conference]

[eCite] [Details]

1998Lyons AB, Simpson CC, 'Marginal zone macrophage regulation of splenic leukocyte migration', 28th Annual meeting of the Australasian Society for Immunology, 29 November - 4 December, Melbourne, Victoria, pp. poster 7-12. (1998) [Conference Extract]

[eCite] [Details]

Co-authors: Simpson CC

1998Lyons AB, Simpson CC, 'Splenic marginal zone macrophages: A multifunctional cell type of dendritic morphology which may interact with dendritic cells', Journal of Leukocyte Biology, September 23-28, Pittsburgh, USA, pp. 77. (1998) [Conference Extract]

[eCite] [Details]

Co-authors: Simpson CC

1998Simpson CC, Lyons AB, 'Control of lymphocyte entry into the spleen by marginal zone macrophages', 37th Annual Meeting of the Australian Society for Medical Research, 22-25 November, Hobart, Tasmania, pp. 71. (1998) [Conference Extract]

[eCite] [Details]

Co-authors: Simpson CC

1996Lee JH, Hodgkin PD, Lyons AB, 'B cell proliferation, division and differentiation in T cell dependent B cell immune reaction', Federation of the Immunological Societies of Asia-Oceania, Adelaide, pp. 110. (1996) [Conference Extract]

[eCite] [Details]

1995Doherty KV, Lyons AB, Hodgkin PD, 'CFSE - A valuable tool for investigating T cell proliferation', Australasian Flow Cytometry Group 18th Annual Meeting, Hobart, Tasmania, pp. No number. (1995) [Conference Extract]

[eCite] [Details]

1995Fulcher DA, Korn SL, Lyons AB, Parish C, Basten A, 'Deletion of autoreactive B cells - stimulation by self-antigen in the absence of T-cell help', 9th International Congress of Immunology, San Francisco, pp. 828. (1995) [Conference Extract]

[eCite] [Details]

1995Lyons AB, 'A fluorescent aggregation assay which allows the identification of the carbohydrate specificity of adhesion molescules involved in cell-cell interactions', Australasian Flow Cytometry Group 18th Annual M eeting, Hobart, Tasmania, pp. No number. (1995) [Conference Extract]

[eCite] [Details]

Other Public Output

(2 outputs)
YearCitationAltmetrics
1998Lyons AB, 'Medical Research Week', Tastalk, Tasmanian branch - AMA, Hobart, October (1998) [Internal Newsletter]

[eCite] [Details]

1998Lyons AB, 'A sound investment in our future health', The Star, Hobart, June 4 (1998) [Newspaper Article]

[eCite] [Details]

Grants & Funding

Funding Summary

Number of grants

32

Total funding

$2,496,475

Projects

Development of a devil facial tumour bait-vaccine for landscape-level distribution (2019)$9,952
Description
This project aims to develop a devil facial tumour (DFT) disease vaccine based on a highly-successful rabies virus vaccine platform. The bait-vaccine approach works by incorporating tumour antigens (i.e. proteins or peptides) into a non-replicating adenovirus in the laboratory, and then packaging the virus into 'blister packs' that are distributed in the landscape for target animals (i.e. devils) to eat. The virus then infects the animal when the blister pack breaks open in the animal's mouth and induces an immune response against the virus and the tumour antigens. To achieve our bait-vaccine goals we need to bring together teams diverse sets of skills, including but not limited to immunologists, geneticists, and ecologists. This research complements our existing devil immunology research but will require the cross-disciplinary expertise of Rick Liu's genetic engineering team to develop the adenovirus-based vaccine platform. The genetic engineering team will harness existing collaborations with the Children's Medical Research Institute to produce the adenoviruses for the devil team's pilot studies. Long-term development of this project will include veterinarians and ecologists from the School of Natural Sciences and DPIPWE. We will apply for funding from the Save the Tasmanian Devil Appeal to develop the field-based aspects of the project. This is likely the only approach that has the potential to eradicate DFT disease from Tasmania.
Funding
University of Tasmania ($9,952)
Scheme
Grant-Research Enhancement Program
Administered By
University of Tasmania
Research Team
Flies AS; Liu R; Lyons AB; Patchett AL; Pye RJ
Year
2019
Studying cancer in wild Tasmanian devils to develop vaccination and early diagnosis methods (2019)$8,698
Description
This project will investigate cell-mediated immunity in wild devils and its relationship with devil facial tumour disease (DFTD). In addition, this project will research small vesicles called exosomes secreted by DFT cells as a potential biomarker for DFTD diagnosis and prognosis.
Funding
National Geographic Society ($8,698)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Lyons AB; Espejo CI
Year
2019
Identification of host-tumour interactions driving immune evasion and survival of devil facial tumor disease (2019)$12,951
Description
This project will use sequencing to generate gene profiles of immune cells in healthy and diseased Tasmanian devils. These datasets will enable identification of immune cell subsets in the Tasmanian devil, and will be mined to detect changes to immune function in diseased devils.
Funding
University of Tasmania ($12,951)
Scheme
Grant-Research Enhancement Program
Administered By
University of Tasmania
Research Team
Patchett AL; Lyons AB; Flies AS
Year
2019
Analytical flow cytometer (2019)$100,000
Description
Purchase of a 5 laser Cytoflex LX flow cytometer. This equipment has the ability to examine the full range of fluorescent proteins used in advanced molecular biology and in complex analyses which are not possible using our current instruments.
Funding
University of Tasmania ($100,000)
Scheme
null
Administered By
University of Tasmania
Research Team
Flies AS; Lyons AB; Pinfold T
Year
2019
Identification of devil facial tumour-associated antigens for vaccine development (2018 - 2019)$34,256
Description
The current DFTD vaccine can induce anti-DFTD immune responses, but the scalability and efficacy of the vaccine needs to be improved to deliver a broad conservation impact. This proposal builds on ongoing vaccine research to identify tumour-associated antigens that can be used to produce a highly replicable and scalable DFTD vaccine.
Funding
University of Tasmania Foundation Inc ($34,256)
Scheme
Grant-Dr Eric Guiler Tasmanian Devil Research Gran
Administered By
University of Tasmania
Research Team
Flies AS; Woods GM; Lyons AB; Wilson RR
Period
2018 - 2019
Good cells battling bad cells: Cell-mediated immunity and transmissible cancer in the Tasmanian devil (2018 - 2019)$10,109
Description
This project is focused in investigating the cell-mediated immunity in wild devils and its relation to DFTD, contributing complementary and relevant information to the current efforts to the vaccine development against DFTD.
Funding
Holsworth Wildlife Research Endowment ($10,109)
Scheme
Grant
Administered By
University of Tasmania
Research Team
Lyons AB; Woods GM; Espejo CI
Period
2018 - 2019
Monitoring DFTD-immunised devils after their release to the wild (2018 - 2019)$19,999
Description
The Save the Tasmanian Devil Programs wild devil recovery project saw the release of 33 devils in 2016. All were immunised against DFTD in a clinical trial by the Menzies Institute for Medical Research. Ongoing monitoring will evaluate the duration of the immunisation responses, and the impact of released devils on the incumbent population.
Funding
University of Tasmania Foundation Inc ($19,999)
Scheme
Grant-Dr Eric Guiler Tasmanian Devil Research Gran
Administered By
University of Tasmania
Research Team
Pye RJ; Fox Samantha; Lyons AB
Period
2018 - 2019
Can the DFTD tumour microenvironment influence vaccine responses in the Tasmanian devil? (2018)$32,775
Description
This project will use sequencing to identify key cell subsets and molecular functions in devil facial tumour disease (DFTD) that are associated with tumour survival and regression. This information will be harnessed for improvement of candidate DFTD therapies and vaccines in the Tasmanian devil.
Funding
University of Tasmania Foundation Inc ($32,775)
Scheme
Grant-Dr Eric Guiler Tasmanian Devil Research Gran
Administered By
University of Tasmania
Research Team
Patchett AL; Lyons AB; Tovar Lopez CD
Year
2018
Immunisation to protect against transmissible cancers in Tasmanian devils (2018 - 2020)$303,931
Funding
Australian Research Council ($303,931)
Scheme
Grant-Discovery Projects
Administered By
University of Tasmania
Research Team
Woods GM; Lyons AB; Corcoran L; Hayball J; Murphy J; Flies AS
Period
2018 - 2020
Grant Reference
DP180100520
A live-attenuated vaccine (DFT-Off) to promote long-term anti-DFTD immunity (2017 - 2018)$35,000
Description
We have developed a system that allows us to switch genes on/off in devil facial tumour (DFT) cells. The DFT-Off cells have the potential to be used as a live-attenuated vaccine, which generally perform better than killed vaccines, that provides long-term protection against both forms of DFT disease (DFTD).
Funding
University of Tasmania Foundation Inc ($35,000)
Scheme
Grant-Dr Eric Guiler Tasmanian Devil Research Gran
Administered By
University of Tasmania
Research Team
Flies AS; Woods GM; Lyons AB
Period
2017 - 2018
Investigation into an overlooked pathway towards anti-cancer immunity. Inhibitory motifs in the extracellular domains of immune checkpoint molecules (2017)$36,155
Description
Checkpoint molecule blockade immunotherapy (e.g. PD-1 monoclonal antibody) has achieved unprecedented success in treating several types of cancer, and ITIM and ITSM signalling play a key role in these treatment approaches. The cancer immunotherapy market reached $16.9 billion in 2015 and is expected to grow to $75 billion by 2022 (GBI 2016). This has greatly improved patient outcomes, but the cost to a single patient can exceed $100,000. The research proposed here has the potential to discover many new drug targets. Importantly, the targets are short peptide sequences, which open the door to using small molecule compounds instead that can be produced and formulated at a significantly lower cost than protein-based therapies. This will benefit cancer patients by reducing the cost for treatment and simultaneously help UTAS enter the rapidly expanding cancer immunotherapy market.
Funding
University of Tasmania Foundation Inc ($36,155)
Scheme
Grant-Cancer Research
Administered By
University of Tasmania
Research Team
Flies AS; Guven N; Blackburn NR; Lyons AB
Year
2017
Developing DFTD vaccination approaches to favour cell mediated anti-tumour immunity (2017 - 2018)$32,304
Description
To successfully vaccinate Tasmanian devils against DFTD, a particular form of response known as cell mediated immunity is needed. This project will test the ability of two distinct approaches to enhance cell mediated immune responses against DFTD.
Funding
University of Tasmania Foundation Inc ($32,304)
Scheme
Grant-Dr Eric Guiler Tasmanian Devil Research Gran
Administered By
University of Tasmania
Research Team
Lyons AB; Patchett AL; Woods GM
Period
2017 - 2018
Evaluation of the role natural killer (NK) cells in protection against DFTD (2017)$26,487
Description
Natural Killer (NK) cells have a major role in the first line of defence against cancer. This project will investigate the presence and function of NK cells in the Tasmanian devil. The ultimate goal is to determine if NK cells are involved in the rejection of DFTD tumours.
Funding
University of Tasmania Foundation Inc ($26,487)
Scheme
Grant-Dr Eric Guiler Tasmanian Devil Research Gran
Administered By
University of Tasmania
Research Team
Woods GM; Lyons AB; Flies AS
Year
2017
Tasmanian Devil Vaccine (2016 - 2018)$537,451
Description
To develop a vaccine against Devil Facial Tumour Disease
Funding
University of Tasmania Foundation Inc ($537,451)
Scheme
Donation - Individual
Administered By
University of Tasmania
Research Team
Woods GM; Lyons AB
Period
2016 - 2018
Translating human cancer immunotherapy techniques for use in pets and Tasmanian devils (2016 - 2017)$140,000
Description
Immunotherapeutics targeting PD-1 and CTLA4 have shown unprecedented success in treating human cancers. Surprisingly, little is known to date on the potential for translating these human immunotherapy approaches into cancer treatments for veterinary medicine. The Tasmanian devil facial tumours (DFTs) and canine transmissible venereal tumour (CTVT) provide unique opportunities to assess immunotherapeutic treatment regimens for two naturally occurring tumours. Our ongoing work on the DFT has already developed ten anti-PD-1, nine anti-PD-L1 (aka B7-H1), and four anti-CTLA4 monoclonal antibodies (mAbs) that are highly specific for devil proteins. We have developed a system that can be used to rapidly generate new mAbs against additional target proteins. Importantly, this system can be readily applied to the production of antibodies that target proteins in other species. We have already begun cloning target genes in dogs, and will begin production of recombinant dog proteins, cell lines, and mAbs in 2016. The devil immunology group will develop dog-specific mAbs, and perform in vitro testing functional testing of the mAbs. The first batch of antibodies for PETization will be delivered to Nexvet in January, 2017. The initial functional testing of the antibodies performed by the devil immunology team will generate vital preliminary data to support planned ARC Linkage Project application in 2016-2017 in order to leverage funds for ongoing collaborative research. Establishing a solid connection between Nexvet and the devil immunology team prior to submission of the ARC Linkage Project application will greatly increase the probability receiving a Linkage Project award and leveraging funds. This research could help save an iconic Australian animal from extinction, develop immunotherapeutics to improve and extend the lives of pets around the world, and help to drive an emerging market for pharmaceuticals for pets.
Funding
Department of Industry and Science ($50,000); Nexvet Australia Pty Ltd ($90,000)
Scheme
Contract Research
Administered By
University of Tasmania
Research Team
Flies AS; Woods GM; Lyons AB; Hayball J
Period
2016 - 2017
Improving the DFTD vaccine by targeting key immune signalling molecules (2016)$35,000
Description
We have discovered that our current vaccine approach of using interferon-gamma (IFNg) to make the DFTD tumour cells visible to the devil immune system also induces upregulation of molecules that inhibit anti-tumour immune responses. We are now modifying the vaccine to counteract the effects of the inhibitory molecules.
Funding
University of Tasmania Foundation Inc ($35,000)
Scheme
Grant-Dr Eric Guiler Tasmanian Devil Research Gran
Administered By
University of Tasmania
Research Team
Flies AS; Woods GM; Lyons AB
Year
2016
Detection of activated Tasmanian devil cytotoxic lymphocytes by a rapid RNA detection assay (2016)$34,999
Description
Monitoring the immune response of vaccinated Tasmanian devils requires analysis of cell mediated immunity .The current assays we use demonstrate killing of DFTD cells but fail to reveal cytotoxic cell activation and themeans of cell death. We plan incorporate a new assay that employs fluorescent in situ hybridisation andbranched DNA amplification technique for simultaneous measurement of RNA transcripts in single cells usingflow cytometry. The advantages of the proposed assay is that it provides a rapid and biologically relevantanalysis of fresh blood samples taken from Tasmanian devils and measures the activity level of these cellsequivalent to when they were in circulation. This will determine if cytotoxic cells are activated to induce targetcell death. We will be able to analyse key gene expression markers for activation such as IFN-gamma andLAMP-I.
Funding
University of Tasmania Foundation Inc ($34,999)
Scheme
Grant-Dr Eric Guiler Tasmanian Devil Research Gran
Administered By
University of Tasmania
Research Team
Pinfold T; Bettiol SS; Woods GM; Lyons AB
Year
2016
Can DFTD cells be made visible to the Tasmanian devil immune system? (2014)$28,000
Description
DFTD should be recognised and rejected by the Tasmanian devil's immune system as a foreign graft, but it appears to be invisible. This project aims to discover if re-expression of MHC molecules allows DFTD cells to be recognised as an allograft and ultimately be killed by the devil immune system. In vitro cell culture techniques and flow cytometry will be used to examine responses. The demonstration that tumour cells can be recognized by cytotoxic T cells will aid the design of immune based strategies for prevention and therapy.
Funding
University of Tasmania Foundation Inc ($28,000)
Scheme
Grant-Dr Eric Guiler Tasmanian Devil Research Gran
Administered By
University of Tasmania
Research Team
Lyons AB; Woods GM
Year
2014
Mechanistic studies of Jack Jumper Venom desensitisation at the T cell level (2014)$5,000
Description
Allergy to Jack Jumper venom is an acute medical emergency which potentially affects >1% of Tasmanians. Desensitisation by venom immunisation therapy (VIT) protects against severe reactions, but the precise mechanism has not been elucidated. This project seeks to understand how immune cells are re-educated to prevent life-threatening allergy.
Funding
Royal Hobart Hospital Research Foundation ($5,000)
Scheme
Grant-Starter
Administered By
University of Tasmania
Research Team
Lyons AB; Wanandy ST; Doherty KV; Brown SG; Wiese MD
Year
2014
Host-tumour Interplay in Tasmanian Devils with Devil Facial Tumour Disease: Can Immune Cells be Harnessed for Therapy? (2013 - 2015)$380,000
Description
Tasmanian devils only exist in Tasmania and Devil Facial Tumour Disease, an infectious cancer, could cause the extinction of the Tasmanian devil. This project will determine if Devil Facial Tumour Disease reduces the effectiveness of the devils immune system and test if activated immune cells can protect against this disease.
Funding
Australian Research Council ($380,000)
Scheme
Grant-Discovery Projects
Administered By
University of Tasmania
Research Team
Woods GM; Lyons AB; Corcoran L
Period
2013 - 2015
Grant Reference
DP130100715
Development of an immune enhancing vaccine to protect Tasmanian devils against a contagious cancer (2013 - 2015)$412,912
Description
The iconic Tasmanian devil is threatened with extinction from a uniformly fatal transmissible facial cancer. This project builds on existing research on the cancer cells that can be recognised by the devil immune system. It will develop and test a vaccine against the tumour, which will ultimately protect devils in the wild.
Funding
Australian Research Council ($412,912)
Scheme
Grant-Linkage Projects Round 1
Administered By
University of Tasmania
Research Team
Woods GM; Lyons AB
Period
2013 - 2015
Grant Reference
LP130100218
MHC-I expression on DFTD tumour cells and monoclonal antibodies as a strategy to induce and analyse an immune response to DFTD (2012)$29,736
Funding
University of Tasmania Foundation Inc ($29,736)
Scheme
Award-Eric Guiler Foundation
Administered By
University of Tasmania
Research Team
Kreiss A; Woods GM; Lyons AB; Tovar Lopez CD
Year
2012
Australasian Society for Immunology 41st Annual Meeting, Adelaide - 11 to 15 December 2011 (Sept 2011) (2011)$1,005
Funding
University of Tasmania ($1,005)
Scheme
Grant-Conference Support Scheme
Administered By
University of Tasmania
Research Team
Lyons AB
Year
2011
1999 Supplementary Funding (1999)$15,000
Funding
University of Tasmania ($15,000)
Scheme
Grant-Supplementary
Administered By
University of Tasmania
Research Team
Lyons AB
Year
1999
B1 cell migration, isotype switching and antigen presentation (1999)$2,500
Funding
Clifford Craig Medical Research Trust/UTAS ($2,500)
Scheme
Grant-Collaborative
Administered By
University of Tasmania
Research Team
Lyons AB
Year
1999
Regulation of lymphocyte entry into the spleen by marginal zone macrophages (1998 - 2000)$144,735
Funding
National Health & Medical Research Council ($144,735)
Scheme
Grant-MRC Project
Administered By
University of Tasmania
Research Team
Lyons AB; Muller HK
Period
1998 - 2000
Grant Reference
981546
Recirculation, Isotope Switching and Antigen Presentation by B-1 B lympphocytes (1998)$7,520
Funding
Clifford Craig Medical Research Trust/UTAS ($7,520)
Scheme
Grant-Collaborative
Administered By
University of Tasmania
Research Team
Lyons AB
Year
1998
Supplementary funding (1997)$15,000
Funding
University of Tasmania ($15,000)
Scheme
Grant-Supplementary
Administered By
University of Tasmania
Research Team
Lyons AB
Year
1997
Superspeed Centrifuge. (1997)$20,000
Funding
National Health & Medical Research Council ($20,000)
Scheme
Grant-Equipment
Administered By
University of Tasmania
Research Team
Woods GM; Kirov SM; Lyons AB; Muller HK
Year
1997
Grant Reference
971378
Recirculation and antigen presentation by B-1 B lymphocytes (1996)$5,000
Funding
Clive & Vera Ramaciotti Foundation ($5,000)
Scheme
Grant-Establishment
Administered By
University of Tasmania
Research Team
Lyons AB
Year
1996
Lymphocyte recirculation and lifespan. (1996)$10,000
Funding
University of Tasmania ($10,000)
Scheme
Grant-Supplementary
Administered By
University of Tasmania
Research Team
Lyons AB
Year
1996
Elite workstation for Flow Cytometry (single user) (1996)$10,000
Funding
National Health & Medical Research Council ($10,000)
Scheme
Grant-Equipment
Administered By
University of Tasmania
Research Team
Woods GM; Dandie GW; Lyons AB; Muller HK
Year
1996
Grant Reference
961451

Research Supervision

Bruce has 5 past HDR completions, and currently supervises or co-supervises 5 PhD students at the University of Tasmania.

Current

6

Completed

6

Current

DegreeTitleCommenced
PhDVaccination-induced Resistance Against DFTD in Tasmanian Devils: Immunisation approaches to enhance immune responses to DFTD2017
PhDNovel Approaches to Treat Viral Pneumonia2017
PhDInsertion of Suicide Genes into DFTD Cancer Cells as Mechanism to Improve Vaccine Efficiency2017
PhDThe Health Impacts of Hazelwood Coal Fire Particles2018
PhDRegulation of Effector Function and Immune Checkpoint Molecules Expression by Cytokines in Tasmanian Devils2019
PhDIdentification of Devil Facial Tumour-Associated Antigens for Vaccine Development2019

Completed

DegreeTitleCompleted
PhDRole of TNF in the Regulation of the Innate Immune Response in Leishmaniasis
Candidate: Shanshan Hu
2018
PhDAn Investigation of the Inhibition of Non-typeable Haemophilus influenzae, by Substances Secreted by Haemophilus haemolyticus
Candidate: Roger Declan Latham
2018
PhDRedefining the Role of Tumour Necrosis Factor in Macrophage Differentiation and Effector Function in Bacterial and Tumour Defences
Candidate: Xinying Li
2018
PhDToll-Like Receptors in the Endangered Tasmanian Devil and Devil Facial Tumour Disease
Candidate: Amanda Louise Patchett
2018
PhDImmune Recognition of Devil Facial Tumour Disease by the Tasmanian Devil
Candidate: Ruth Jacqueline Pye
2017
PhDManipulating the Immune Response of Tasmanian Devils to Target Devil Facial Tumour Disease
Candidate: Gabriella Kathleen Brown
2013